AP3

What this means for you

This application is over — abandoned 24 Mar 2026. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number

98851818

Mark type

Stylized text

Filed

13 Nov 2024

Abandoned

24 Mar 2026

Attorney of record

Sara M. Bauer

Goods and services

• Class 042 — Scientific and technological services: scientific research; medical research; proteomics and biomarker discovery services, namely, medical testing services and information in the field of disease classification; scientific research and development in the fields of pharmaceuticals, therapeutics, and drug formulation and delivery; scientific research and development in the fields of proteomics and biomarker discovery; consultancy services in the field of pharmaceutical research and development services; consultancy services in the fields of medical and scientific research concerning proteomics and biomarker discovery; pharmaceutical research services related to prediction of drug treatment efficacy; medical research services related to prediction of drug treatment efficacy; conducting scientific studies in the fields of proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder identification; proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder identification; providing information in the field of medical, scientific and pharmaceutical research about proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder indication services; scientific and technological research and consultation services, namely, in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, pharmacodynamic biomarkers, drug repurposing, patient responder identification, indication finding, and rational drug design; drug discovery services in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers, drug repurposing, and rational drug design through optimal pathway effects in intact cells; consultancy in the field of pharmaceutical research and development services in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers, drug repurposing, indication finding, and rational drug design through pathway-based SAR
• Class 044 — Medical, beauty and agricultural services: Medical services; medical testing for diagnosis or treatment purposes; medical diagnostic testing, monitoring, and reporting services; providing medical information, consultancy and advisory services; individual medical counseling services provided to patients; providing a website featuring information in the field of precision medicine; providing medical information to medical professionals in the form of reports in the field of precision medicine; proteomics and biomarker discovery services, namely, medical diagnostic services

Owner

• Acrivon Therapeutics, Inc., Watertown, MA, US

Prosecution history

• 25 Mar 2026 — ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
• 25 Mar 2026 — ABANDONMENT - EXPRESS MAILED
• 24 Mar 2026 — TEAS EXPRESS ABANDONMENT RECEIVED
• 06 Feb 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 06 Feb 2026 — NON-FINAL ACTION E-MAILED
• 06 Feb 2026 — NON-FINAL ACTION WRITTEN
• 28 Aug 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
• 28 Aug 2025 — LETTER OF SUSPENSION E-MAILED
• 28 Aug 2025 — SUSPENSION LETTER WRITTEN
• 07 Jul 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 07 Jul 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 07 Jul 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 09 Jun 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 09 Jun 2025 — NON-FINAL ACTION E-MAILED
• 09 Jun 2025 — NON-FINAL ACTION WRITTEN